Scancell HoldingsSCNLF 20 ROA % is -60.28% as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Scancell Holdings ranks better than 51.2% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Scancell Holdings's annualizedNet Income for the quarter that ended in Oct. 2025 was $-15.33 Mil.
Scancell Holdings's average Total Assets over the quarter that ended in Oct. 2025 was $25.44 Mil. Therefore, Scancell Holdings's annualized ROA % for the quarter that ended in Oct. 2025 was -60.28%.
The historical rank and industry rank for Scancell Holdings's ROA % or its related term are showing as below:
SCNLF'
s ROA % Range Over the Past 10 Years
Min: -56.88 Med: -39.51 Max: -10.86
Current: -30.02
During the past 13 years, Scancell Holdings's highest ROA % was -10.86%. The lowest was -56.88%. And the median was -39.51%.
SCNLF's ROA % is ranked better than 51.2% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs SCNLF: -30.02
Scancell Holdings (OTCPK:SCNLF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Oct. 2025) net income data. The Revenue data used here is two times the semi-annual (Oct. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Scancell Holdings ROA % Related Terms
Scancell Holdings ROA % Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Scancell Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's ROA % distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Oct. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Scancell Holdings (SCNLF) has a ROA % of -60.28% as of Oct. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #694 out of 1422 companies in the Biotechnology industry, placing it in the top 48.8%.
Is Scancell Holdings' ROA % too high?
Scancell Holdings' current ROA % is -60.28%. Based on the distribution chart, Scancell Holdings ranks #694 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #694 out of 1422 companies for ROA %. This puts Scancell Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current ROA % is -60.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current ROA % of -60.28%. The current ROA % is -60.28%. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current ROA % is -60.28% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
